Estonia’s Rise as Europe’s Fintech Powerhouse
Estonia, a small Baltic country with a population of 1.4 million, is in the news for all the right reasons: its burgeoning fintech sector. With a market size of €15.2 billion...
Open Banking Sparking a Wave of Innovation in Financial Services
The adoption of open banking is leading to innovation across financial solutions such as account-to-account payments (A2A), personal finance management (PFM) apps, embedded finance, and banking-as-a-service (BaaS) by enabling real-time...
New Directions in Alzheimer’s Diagnostics: Will Blood Tests Replace CSF and PET?
Around three-fourths of dementia cases continue to remain undiagnosed even though the incidence of Alzheimer’s disease (AD) is rapidly growing across the globe. AD affects about 60-80% of dementia patients...
Phase 3 Drug Candidates – A Ray of Hope in Alzheimer’s Disease Bleak Treatment Landscape?
Many biopharmaceutical companies, such as AriBio, Annovis Bio, Athira Pharma, Cassava Sciences, and Alzheon, specializing in treating neurodegenerative diseases, are developing drugs for Alzheimer’s disease (AD) that are currently in...
What’s Fueling Asia’s Drive to Develop Wholesale CBDCs?
The emergence of Central Bank Digital Currencies (CBDCs) has become a central focus in the global financial space, as it offers the potential for revolutionary shifts in how the world...
Charting the RegTech Journey: Navigating Consolidation
RegTech, short for regulatory technology and often categorized as a subset of fintech, emerged in 2015. The RegTech industry was fragmented, with numerous small players targeting specific niches within the...
IRA: Are Patients Winning at the Cost of the US Pharma Sectoral Growth?
The market reaction to the US Inflation Reduction Act of 2022 is mostly mixed. It is expected to change the pharma industry dynamics in terms of the competitive positioning and...
An Era of Innovation: Novel Drugs Redefining Multiple Sclerosis Treatment Paradigm
Since the approval of the first drug, interferon beta 1b (IFNβ-1b), in 1993, the treatment landscape of multiple sclerosis (MS) has significantly changed. Currently, there exist more than 20 disease-modifying...